Amoxicillin Dosing for Adult Bacterial Respiratory Tract Infections
Standard Dosing
For adults with mild bacterial respiratory tract infections and no recent antibiotic use (within 4-6 weeks), amoxicillin 1.5-4 g/day divided every 8-12 hours is recommended, with higher doses (4 g/day) preferred in areas with high rates of penicillin-resistant Streptococcus pneumoniae or for patients with moderate disease. 1
Dosing by Disease Severity
Mild disease (no recent antibiotics):
- Amoxicillin 500-1000 mg every 8 hours (1.5-3 g/day) 2
- Alternative: Amoxicillin 1.5-4 g/day divided doses 1
Moderate disease or recent antibiotic use:
- High-dose amoxicillin 4 g/day is strongly preferred 1
- This provides better coverage against drug-resistant S. pneumoniae (penicillin MIC ≥2 μg/mL) 1
The rationale for high-dose therapy is that amoxicillin serum levels increase linearly with dose, and higher doses overcome relative penicillin resistance in pneumococci without significantly increasing adverse effects 1.
β-Lactamase-Producing Organisms
When β-lactamase-producing organisms (Haemophilus influenzae, Moraxella catarrhalis) are suspected or confirmed, switch to amoxicillin-clavulanate rather than plain amoxicillin. 1
- Standard dose: Amoxicillin-clavulanate 1.75-4 g/250 mg per day 1
- High-dose formulation: Amoxicillin-clavulanate 4 g/250 mg per day (2000 mg/125 mg twice daily) 1
The high-dose formulation (Augmentin XR) provides pharmacokinetically enhanced amoxicillin exposure while maintaining clavulanate coverage against β-lactamase producers 3, 4. This formulation maintains plasma amoxicillin concentrations above 4 μg/mL for approximately 49% of the dosing interval, ensuring efficacy against resistant strains 4.
Renal Impairment Adjustments
Dose reduction is required only for severe renal impairment (GFR <30 mL/min). 5
The FDA label specifies that amoxicillin is primarily eliminated by the kidney and dosage adjustment is necessary in severe renal impairment 5. However, recent evidence suggests that immediate dose reduction in patients with acute kidney injury (AKI) on admission may be premature 6. In patients with respiratory infections, 27.1% present with AKI, and 57.2% of these cases resolve within 48 hours 6. Consider deferring renal dose adjustment for the first 48 hours in patients with AKI to avoid underdosing during critical early treatment.
Specific adjustments for GFR <30 mL/min:
- Reduce dose or extend dosing interval
- Monitor renal function closely
- Elderly patients require particular attention as they are more likely to have decreased renal function 5
Penicillin Allergy
For patients with documented Type I hypersensitivity (anaphylaxis, urticaria, angioedema within 1-6 hours), avoid all penicillins and use a respiratory fluoroquinolone (levofloxacin 750 mg daily, moxifloxacin 400 mg daily) instead. 1
Important Allergy Considerations:
- Cross-reactivity with cephalosporins is <1% for most penicillin-allergic patients, but can exceed 30% with aminocephalosporins (cefuroxime, cefpodoxime) due to shared side-chain structures 7
- Non-Type I reactions (e.g., rash occurring >1 hour after administration): Cephalosporins can be considered 1
- Most reported penicillin allergies are not true allergies - over 90% of patients labeled "penicillin allergic" can actually tolerate β-lactams 8, 9
Alternative agents for true β-lactam allergy:
- Respiratory fluoroquinolones (preferred): levofloxacin, moxifloxacin 1
- Macrolides/azalides: azithromycin, clarithromycin - but expect 20-25% bacteriologic failure rates 1
- Doxycycline: 100 mg every 12 hours 2
Critical Pitfall:
TMP/SMX, doxycycline, and macrolides should not be used as first-line agents unless the patient has a true β-lactam allergy, as their effectiveness against major respiratory pathogens is limited with bacterial failure rates of 20-25% 1. The widespread inappropriate use of fluoroquinolones for mild disease promotes resistance 1.